Table 1 Overall CML Patient Characteristics (n = 87 patients)
Characteristic | # of Patients (%) |
|---|---|
Age in years (n = 86) | Â |
   <60 | 79 (91.9%) |
   >/=60 | 7 (8.1%) |
Gender (n = 87) | Â |
   Male | 44 (50.6%) |
   Female | 43 (49.4%) |
Ethnicity (n = 87) | Â |
   Hispanic | 53 (60.9%) |
   Non-Hispanic | 34 (39.1%) |
White | 4 (4.6%) |
African American | 10 (11.5%) |
Asian | 20 (23.0%) |
Imatinib Treatment (n = 64) | Â |
   Yes | 40 (62.5%) |
   No | 24 (37.5%) |
Hemoglobin (g/dL) (n = 83) | Â |
   <12 | 57 (68.7%) |
   >/=12 | 26 (31.3%) |
WBC count (× 109/L) (n = 85) |  |
   <50 | 22 (25.9%) |
   >/=50 | 63 (74.1%) |
Platelets (× 109/L) (n = 82) |  |
   <450 | 50 (61.0%) |
   >/=450 | 32 (39.0%) |
CML Phase (n = 74) | Â |
   Chronic | 68 (91.9%) |
   Accelerated | 4 (5.4%) |
   Blastic | 2 (2.7%) |
Hasford Score (n = 64) | Â |
   </=780 low-risk | 35 (54.7%) |
   >780 and </=1480 intermediate | 21 (32.8%) |
   >1480 high-risk | 8 (12.5%) |
Sokal Score (n = 65) | Â |
   <0.8 good prognosis | 25 (38.5%) |
   0.8–1.2 moderate prognosis | 24 (36.9%) |
   >1.2 poor prognosis | 16 (24.6%) |
CHR at 3 months, all treatments (n = 47) | Â |
   Yes | 28 (59.6%) |
   No | 19 (40.4%) |
CHR at 3 months, imatinib only (n = 36) | Â |
   Yes | 27 (75%) |
   No | 9 (25%) |